Mankind Pharma to Invest EUR 50Mn, Acquire 70% in ACTx

Mankind Pharma Limited's Board of Directors has approved an additional investment of up to EUR 45Mn in its wholly-owned subsidiary, Mankind Pharma (Netherlands) B.V., increasing the total investment limit to EUR 50Mn. This capital will be utilized by the subsidiary to acquire a 70% majority stake in Armed Cell Therapeutics B.V. (ACTx), a Belgium-based biotechnology company specializing in next-generation CAR-T therapies for cancer. ACTx's lead programs target non-Hodgkin lymphoma and small cell lung cancer. This strategic move marks Mankind Pharma's entry into advanced cancer therapy development, aligning with its long-term strategy for a global innovation-led pharmaceutical business. The acquisition is part of a cash consideration, to be paid in installments.